Impact BioMedical Inc. announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic all-equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact BioMedical’s focused roll-up strategy, expanding its portfolio with cutting-edge solutions.
The transaction involved the payment of $1.15 million in common stock. The acquired assets included approximately $489,000 in inventory related to the Celios air purification system and $325,000 in intellectual property. An additional $330,000 premium was recorded directly to equity.
The Celios® technology focuses on providing clean-room air quality, protecting people, plants, and animals from dangerous pathogens. This acquisition diversifies Impact BioMedical's offerings and provides a new avenue for potential commercialization within the health and wellness sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.